We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020

By LabMedica International staff writers
Posted on 05 Feb 2020
Print article
Illustration
Illustration
Randox Biosciences, a part of Randox Laboratories, (Crumlin, UK), showcased its new Vivalytic molecular diagnostic platform at MEDLAB Middle East, the largest medical laboratory exhibition and congress in the Middle East & North Africa (MENA) region.

Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.

Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.

At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.

Related Links:
Randox Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.